灵麦项目推荐LMLB121 - 动次打次！动次打次！德国多动症ADHD王牌产品LMP1087

欢迎分享，转载有版权, 快快登录 lingmed.net/reports 下载全文吧

本周灵麦医药给您推荐一款来自德国的治疗多动症（ADHD）的项目

注意缺陷多动障碍（ADHD），俗称多动症，儿童期常见的一类心理障碍，主要症状是注意力散涣或集中困难、活动量过多且自制力弱。LMP1087最初于2015年在德国上市，现已占据德国市场地46%的市场份额（位居第一位）以及24%的欧洲市场份额（暂居第二位）。至今，已有16个系统的临床试验可以证明其有效性。

• 2016年全球及中国ADHD市场情况及2022年未来市场预测

• LMP1087项目背景，全球竞争格局及中国重点公司

Bang Bang Bang- Leading ADHD Brand in Germany 

  

This week Lingmed shares with you a novel asset in the area of ADHD. Attention-deficit/hyperactivity disorder (ADHD) is a brain disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. LMP1087 has marketed in Germany in 2015 and occupied 46% market share (the leading brand) in Germany and 24% market share in Europe. Up to now, there are 16 clinical trials to show its efficacy and safety.  

• Worldwide and Chinese ADHD market analysis in 2016 and market forecast in 2022

• The  product profile, competitive landscape and leading companies of LMP1087

想要下载完整报告? 

请登录 www.lingmed.net/reports

或点击下方“阅读原文”马上下载